Citius Pharmaceuticals, Inc. (CTXR) shareholders
Close on Nov 17, 2026Market cap $14.24MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (9.90%) | 3,008,529 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Leonard L. Mazur | 754,295 | 9.30% | 13D (active) amendment | Nov 25, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CTXR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 215,537 | 0.79% | $130.30K | −30,621 | 0.00% |
| Vanguard Capital Management LLC | 197,364 | 0.72% | $119.41K | +29,626 | 0.00% |
| Miller Financial Services LLC | 130,000 | 0.47% | $78.59K | +116,000 | 0.06% |
| Citadel Advisors LLC | 124,910 | 0.46% | $75.51K | New | 0.00% |
| Jane Street Group, LLC | 122,837 | 0.45% | $74.26K | +100,314 | 0.00% |
| Vanguard Fiduciary Trust Co | 77,755 | 0.28% | $47.04K | – | 0.00% |
| BlackRock, Inc. | 69,850 | 0.25% | $42.22K | −1 | 0.00% |
| Northern Trust Corp | 62,742 | 0.23% | $37.93K | +18,768 | 0.00% |
| XTX Topco Ltd | 59,199 | 0.22% | $35.79K | +37,904 | 0.00% |
| Asset Advisory Group, Inc. | 59,011 | 0.21% | $35.67K | – | 0.02% |
| BostonPremier Wealth LLC | 28,000 | 0.10% | $16.93K | New | 0.01% |
| UBS Group AG | 26,335 | 0.10% | $15.93K | −28,690 | 0.00% |
| LPL Financial LLC | 25,445 | 0.09% | $15.38K | +400 | 0.00% |
| State Street Corp | 23,271 | 0.08% | $14.07K | – | 0.00% |
| Virtu Financial LLC | 20,836 | 0.08% | $13.00K | New | 0.00% |
| Arkadios Wealth Advisors | 20,000 | 0.07% | $12.09K | – | 0.00% |
| Two Sigma Investments, LP | 17,494 | 0.06% | $10.58K | +4,356 | 0.00% |
| Sanctuary Advisors, LLC | 11,810 | 0.04% | $7.14K | New | 0.00% |
| Susquehanna International Group, Llp | 11,795 | 0.04% | $7.13K | −25,043 | 0.00% |
| R Squared Ltd | 11,033 | 0.04% | $6.67K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 43 | 1M | 5.0% | 13 / 8 | 9 / 8 | 1M | 0M |
| Q1 2026 | 38 | 1M | 3.6% | 9 / 7 | 6 / 9 | 0M | 1M |
| Q4 2025 | 39 | 2M | 6.3% | 9 / 8 | 7 / 4 | 1M | 0M |
| Q3 2025 | 34 | 1M | 2.3% | 8 / 10 | 4 / 5 | 0M | 1M |
| Q2 2025 | 31 | 1M | 3.4% | 8 / 6 | 6 / 5 | 1M | 0M |
| Q1 2025 | 28 | 1M | 2.3% | 5 / 7 | 7 / 6 | 0M | 0M |
| Q4 2024 | 30 | 1M | 2.2% | 30 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
5 funds held CTXR in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CTXR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 167,738 | 0.61% | $101.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 148,094 | 0.54% | $96.99K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 26,359 | 0.10% | $17.26K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 11,655 | 0.04% | $7.63K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1,862 | -0.01% | -$1.13K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | 410,214 | 1.49% | Sep 23, 2025 |
| Myron Z. Holubiak | Vice Chairman, Director | 79,690 | 0.29% | Aug 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eugene Myron Holuka Director | Mar 13, 2024 | Tax withholding | −48 | $0.75 | $36 | 2,367 |
| Eugene Myron Holuka Director | Mar 13, 2024 | Option exercise | +2,415 | $0.02 | $48 | 2,415 |
| Carol Webb Director | Mar 4, 2024 | Tax withholding | −236 | $0.77 | $182 | 11,835 |
| Carol Webb Director | Mar 4, 2024 | Option exercise | +12,071 | $0.02 | $241 | 12,071 |
| Myron Z. Holubiak President and CEO, Director, 10% owner | Sep 27, 2019 | Buy | +558,597 | $0.90 | $502.74K | 1,992,243 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Sep 27, 2019 | Buy | +2,234,700 | $0.90 | $2.01M | 10,255,343 |
| Myron Z. Holubiak President and CEO, Director, 10% owner | Apr 3, 2019 | Buy | +129,450 | $1.55 | $200.65K | 1,433,646 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Apr 3, 2019 | Buy | +1,165,048 | $1.55 | $1.81M | 8,020,643 |
| Myron Z. Holubiak President and CEO, Director, 10% owner | Aug 13, 2018 | Buy | +784,314 | $1.28 | $1.00M | 1,304,196 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 13, 2018 | Buy | +3,137,255 | $1.28 | $4.02M | 6,855,595 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Mar 29, 2018 | Buy | +167,504 | $2.99 | $500.84K | 3,718,340 |
| Myron Z. Holubiak President and CEO, Director | Mar 28, 2018 | Buy | +2,915 | $3.09 | $9.01K | 519,882 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Dec 19, 2017 | Buy | +213,106 | $4.69 | $999.47K | 3,550,836 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 24, 2017 | Buy | +11,000 | $2.68 | $29.48K | 3,337,730 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 8, 2017 | Conversion | +1,547,067 | $3.09 | $4.78M | 3,326,730 |
| Leonard L. Mazur Executive Chairman, Director, 10% owner | Aug 8, 2017 | Buy | +421,400 | $4.13 | $1.74M | 1,779,663 |
| Leonard L. Mazur Director | Mar 30, 2016 | Buy | +5,000,000 | $0.60 | $3.00M | 5,457,143 |
| Leonard L. Mazur Director | Mar 30, 2016 | Other | +15,116,746 | – | – | 20,116,746 |
| Myron Z. Holubiak President and CEO, Director | Mar 30, 2016 | Other | +7,754,497 | – | – | 7,754,497 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Citius Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 104,774 shares on Aug 21, 2026 over the last 90 days.
See a number that looks wrong?